Reply To: “Interleukin-22 in Acute-on-chronic Liver Failure: A Matter of Ineffective Levels, Receptor Dysregulation or Defective Signalling?”
Xiaogang Xiang,Seonghwan Hwang,Bin Gao
DOI: https://doi.org/10.1016/j.jhep.2020.06.002
IF: 25.7
2020-01-01
Journal of Hepatology
Abstract:Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?Journal of HepatologyVol. 73Issue 4PreviewXiang et al. published interesting insights about the role of interleukin (IL)-22 in acute-on-chronic liver failure (ACLF).1 The authors elegantly analysed the effects of IL-22 in a mouse model of ACLF after chronic carbon tetrachloride (CCl4)-treatment (0.2 ml/kg, 2×/week, i.p.) and acute precipitating injury using 2 injections of 0.4 ml/kg CCl4 in combination with an i.p. challenge with Klebsiella pneumonia (K.P.), mimicking a bacterial infection. The model seems to induce a shift in the hepatic IL-22 signalling from the pro-regenerative IL-6/STAT3 towards the anti-regenerative IFNγ/STAT1 pathway paralleled by suppression of liver regeneration. Full-Text PDF Open AccessInterleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in miceJournal of HepatologyVol. 72Issue 4PreviewAcute-on-chronic liver failure (ACLF) is a clinical syndrome defined by liver failure on pre-existing chronic liver disease. It is often associated with bacterial infection and high short-term mortality. Experimental models that fully reproduce ACLF are lacking, so too are effective pharmacological therapies for this condition. Full-Text PDF We greatly appreciate Schwarzkopf et al.'s comments on our work. The first question raised relates to the role of endogenous interleukin (IL)-22 and IL-22 binding protein (IL-22BP) in acute-on-chronic liver failure (ACLF). Serum levels of IL-22 are elevated in patients with ACLF[1]Schwarzkopf K. Ruschenbaum S. Barat S. Cai C. Mucke M.M. Fitting D. et al.IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure.Hepatol Commun. 2019; 3: 392-405Crossref PubMed Scopus (25) Google Scholar and in mouse models of ACLF induced by infection of adenovirus-CYP4502D6 plus injection of cecal slurry (CS) or chronic CCl4 plus 2 binges of ethanol.[2]Schwarzkopf K. Eberle L. Uschner F. Klein S. Schierwagen R. Muecke M. et al.Interleukin-22 (IL-22) in acute-on-chronic liver failure: a matter of ineffective levels, receptor dysregulation or defective signaling?.J Hepatol. 2020; 72: 736-745PubMed Google Scholar Actually, we also found that serum IL-22 levels were mildly but significantly elevated in our ACLF model, which was illustrated in Fig. S6B in our paper.[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar The role of this endogenous IL-22 elevation in ACLF, which was not the focus of our study, remains obscure, although endogenous IL-22 has been shown to protect against acute liver injury[4]Zenewicz L.A. Yancopoulos G.D. Valenzuela D.M. Murphy A.J. Karow M. Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation.Immunity. 2007; 27: 647-659Abstract Full Text Full Text PDF PubMed Scopus (528) Google Scholar and bacterial infection in mice.[5]Zheng M. Horne W. McAleer J.P. Pociask D. Eddens T. Good M. et al.Therapeutic role of interleukin 22 in experimental intra-abdominal Klebsiella pneumoniae infection in mice.Infect Immun. 2016; 84: 782-789Crossref PubMed Scopus (26) Google Scholar One enigma is that humans have a thousand-fold higher circulating IL-22BP than mice (~40,000–70,000 pg/ml in humans vs. ~40 pg/ml in mice)[1]Schwarzkopf K. Ruschenbaum S. Barat S. Cai C. Mucke M.M. Fitting D. et al.IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure.Hepatol Commun. 2019; 3: 392-405Crossref PubMed Scopus (25) Google Scholar,[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar; the reason for this huge difference is not clear. Although IL-22BP has been shown to inhibit IL-22 signaling, the degree to which IL-22BP inhibits IL-22 signaling remains unclear, and the exact functions of IL-22BP still remain obscure. It is plausible that endogenous IL-22 may have less significant functions in humans than in mice because of much higher IL-22BP levels in humans; however, this speculation needs to be confirmed. Nevertheless, we agree with the hypothesis by Schwarzkopf et al. that the ineffective hepatoprotection by endogenous IL-22 in patients with ACLF may be due to high levels of IL-22BP.[1]Schwarzkopf K. Ruschenbaum S. Barat S. Cai C. Mucke M.M. Fitting D. et al.IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure.Hepatol Commun. 2019; 3: 392-405Crossref PubMed Scopus (25) Google Scholar,[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar However, the pharmacological treatment with IL-22Fc, which was the focus of our study, caused a several thousand-fold increase in serum IL-22 (~700,000 pg/ml after IL-22Fc vs. ~200 pg/ml before IL-22Fc) and great biological responses in healthy volunteers[6]Tang K.Y. Lickliter J. Huang Z.H. Xian Z.S. Chen H.Y. Huang C. et al.Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.Cell Mol Immunol. 2019; 16: 473-482Crossref PubMed Scopus (45) Google Scholar,[7]Rothenberg M.E. Wang Y. Lekkerkerker A. Danilenko D.M. Maciuca R. Erickson R. et al.Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury.Clin Pharmacol Ther. 2019; 105: 177-189Crossref PubMed Scopus (32) Google Scholar and in patients with alcoholic hepatitis.[8]Arab J.P. Sehrawat T.S. Simonetto D.A. Verma V.K. Feng D. Tang T. et al.An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis.Hepatology. 2019; https://doi.org/10.1002/hep.31046Crossref PubMed Scopus (67) Google Scholar IL-22Fc is a recombinant fusion protein consisting of 2 human IL-22 molecules linked to an immunoglobulin constant region (IgG-Fc) and has a long half-life in vivo.[6]Tang K.Y. Lickliter J. Huang Z.H. Xian Z.S. Chen H.Y. Huang C. et al.Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.Cell Mol Immunol. 2019; 16: 473-482Crossref PubMed Scopus (45) Google Scholar,[7]Rothenberg M.E. Wang Y. Lekkerkerker A. Danilenko D.M. Maciuca R. Erickson R. et al.Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury.Clin Pharmacol Ther. 2019; 105: 177-189Crossref PubMed Scopus (32) Google Scholar Such high levels of IL-22Fc can probably overcome the inhibitory function of IL-22BP and ameliorate ACLF by activating the pro-regenerative STAT3 signaling in hepatocytes. Schwarzkopf et al. proposed a mouse model of ACLF induced by infection of adenovirus-CYP4502D6 plus injection of CS.[2]Schwarzkopf K. Eberle L. Uschner F. Klein S. Schierwagen R. Muecke M. et al.Interleukin-22 (IL-22) in acute-on-chronic liver failure: a matter of ineffective levels, receptor dysregulation or defective signaling?.J Hepatol. 2020; 72: 736-745PubMed Google Scholar We agree that CS is a good approach for inducing ACLF in mice due to induction of polymicrobial infection. Actually, we attempted to develop a CS-induced ACLF model as well. We prepared the CS according to a recently published CS preparation protocol[9]Starr M.E. Steele A.M. Saito M. Hacker B.J. Evers B.M. Saito H. A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis.PLoS One. 2014; 9: e115705Crossref PubMed Scopus (82) Google Scholar and injected a high dose of 200 μl/mouse as suggested by this protocol.[9]Starr M.E. Steele A.M. Saito M. Hacker B.J. Evers B.M. Saito H. A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis.PLoS One. 2014; 9: e115705Crossref PubMed Scopus (82) Google Scholar Although 40% mortality was reported in young mice after injection of this dose in this protocol,[9]Starr M.E. Steele A.M. Saito M. Hacker B.J. Evers B.M. Saito H. A new cecal slurry preparation protocol with improved long-term reproducibility for animal models of sepsis.PLoS One. 2014; 9: e115705Crossref PubMed Scopus (82) Google Scholar we failed to observe mortality in mice by injecting this CS dose although the blood cultures showed positive results (Fig. 1). We believe that this CS approach is highly dependent on the conditions of animal facilities and thus hard to control. For example, mice in our animal facility at the NIAAA are provided with water of pH ~7, whereas mice at the Jackson laboratory are given acidic water (pH ~2). This difference could greatly impact gut bacteria and the outcome of the CS injection experiment. In addition, we also performed cecal ligation and puncture (CLP) surgery to induce multi-bacterial infections in our ACLF model and found that CLP caused a similar pathological process and mortality like Klebsiella pneumonia (K.P.) injection.[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar However, in the CLP model, it is hard to accurately control the spillage amount of cecal contents into the peritoneal cavity, and the surgical procedure and environment of the animal facility significantly influence the outcome of the model. In contrast, a single K.P. injection is easy to handle and the dose of K.P. can be controlled precisely.[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar Therefore, we prefer a single K.P. injection to introduce bacterial infection in the ACLF model with chronic plus acute CCl4 injection.[3]Xiang X. Feng D. Hwang S. Ren T. Wang X. Trojnar E. et al.Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020; 72: 736-745Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar Lastly, establishment of ACLF in mice by combination of alcohol binges and chronic CCl4 treatment, as shared by Schwarzkopf et al., is of great interest to us at the NIAAA. We have not tested alcohol binges in our ACLF model, but it will be exciting to further explore this model and investigate the mechanism underlying the precipitating effect of alcohol binge in the course of alcohol-associated ACLF development. Again, we thank Schwarzkopf et al. for raising several stimulating questions. Because IL-22 has many beneficial functions in the liver and has shown promise in a phase IIb trial in patients with alcoholic hepatitis,[8]Arab J.P. Sehrawat T.S. Simonetto D.A. Verma V.K. Feng D. Tang T. et al.An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis.Hepatology. 2019; https://doi.org/10.1002/hep.31046Crossref PubMed Scopus (67) Google Scholar it is worth exploring IL-22 therapy in ACLF and other of liver diseases, such as non-alcoholic steatohepatitis.[10]Hwang S. He Y. Xiang X. Seo W. Kim S.J. Ma J. et al.Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets.Hepatology. 2019; https://doi.org/10.1002/hep.31031Crossref Scopus (61) Google Scholar Further studies are needed to clarify the role of endogenous IL-22 and IL-22BP in the pathogenesis of liver diseases. This work was supported by the intramural program of NIAAA, NIH, United States (B.G.). XX performed the experiment for the Fig. 1 and wrote the paper; SH wrote and edited the paper; BG supervised the whole project, wrote and edited the paper. The authors declare no competing interests. Please refer to the accompanying ICMJE disclosure forms for further details. Download .pdf (.24 MB) Help with pdf files disclosures.pdf